Greenwich LifeSciences (GLSI) Change in Accured Expenses (2019 - 2026)
Greenwich LifeSciences' (GLSI) quarterly Change in Accured Expenses came in at $236620.0 in Q4 2025, down 14.5% YoY from $276745.0 in Q4 2024, and up 90.85% on a QoQ basis from $123982.0 in Q3 2025.
Powered by 
Analysis
Greenwich LifeSciences (GLSI) Change in Accured Expenses (2019 - 2026) Analysis & Trends
Greenwich LifeSciences (GLSI) has 7 years of Change in Accured Expenses data on file, last reported at $236620.0 in Q4 2025.
- Quarterly Change in Accured Expenses fell 14.5% year-over-year to $236620.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $367538.0 (up 20.0% YoY) and the FY2025 annual result came in at $367538.0, up 20.0% from the prior year.
- Change in Accured Expenses grew to $236620.0 in Q4 2025, from $123982.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $276745.0 in Q4 2024 to a low of -$144004.0 in Q1 2022.
- A 5-year average of $29209.4 and a median of $6693.0 in 2024 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 3313.66% — and 2024, when it surged 1078.04%.
- Tracing GLSI's Change in Accured Expenses over 5 years: stood at -$63301.0 in 2021, then soared by 139.53% to $25026.0 in 2022, then slumped by 213.07% to -$28296.0 in 2023, then surged by 1078.04% to $276745.0 in 2024, then declined by 14.5% to $236620.0 in 2025.
- The last three Change in Accured Expenses figures came in at $236620.0 (Q4 2025), $123982.0 (Q3 2025), and -$1510.0 (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Greenwich LifeSciences | 231.59 Mn | 231.59 Mn | - | -224,114.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -224,114.00 |
| Dec 31, 2025 | 236,620.00 |
| Sep 30, 2025 | 123,982.00 |
| Jun 30, 2025 | -1,510.00 |
| Mar 31, 2025 | 8,446.00 |
| Dec 31, 2024 | 276,745.00 |
| Sep 30, 2024 | 49,828.00 |
| Jun 30, 2024 | -25,232.00 |
| Mar 31, 2024 | 4,940.00 |
| Dec 31, 2023 | -28,296.00 |
| Sep 30, 2023 | 65,302.00 |
| Jun 30, 2023 | -13,647.00 |
| Mar 31, 2023 | -27,330.00 |
| Dec 31, 2022 | 25,026.00 |
| Sep 30, 2022 | 8,745.00 |
| Jun 30, 2022 | -12,034.00 |
| Mar 31, 2022 | -144,004.00 |
| Dec 31, 2021 | 5,053.00 |
| Sep 30, 2021 | 63,301.00 |
| Jun 30, 2021 | 18,303.00 |